| 查看: 1570 | 回复: 5 | |||
[交流]
【讨论】非索非那定的市场情况
|
|
求:非索非那定的 一、产品研发背景 1. 原研厂家 2. 研发时间与研究立意 3.国外的上市与销售情况 二、与现有竞争产品的比较 三、国内市场情况 1.批文数量及厂家(含规格) 2. 历史销售情况及分析 3.国内主要生产厂家的销售情况 |
» 猜你喜欢
己酮可可碱过氧化杂质限度
已经有2人回复
计算化学与人工智能驱动的MOFs性能预测与筛选技术
已经有0人回复
药理学论文润色/翻译怎么收费?
已经有181人回复
求助Isoeugenol质量标准
已经有0人回复
Gliclazide
已经有0人回复
塞替派/噻替哌(Thiotepa) 质量控制
已经有16人回复
研三实验求指导
已经有0人回复
有没有大佬可以帮忙查下Trijardy XR和Qternmet XR历年销售数据呀
已经有0人回复
金属材料多尺度计算模拟技术与应用:微观机理到宏观性能的集成工作
已经有0人回复
酰胺水解求助
已经有11人回复
中药材标准目录大全llp2026(含各省市中药材和炮制规范)
已经有0人回复
» 本主题相关价值贴推荐,对您同样有帮助:
现在国内有那几家在生产毒莠定?市场情况如何?
已经有4人回复
» 抢金币啦!回帖就可以得到:
限广州,征女友
+2/180
哈尔滨工业大学王东博课题组/中科院上海微系统所梁丽娟课题组招收2026年博士生1名
+1/85
供应EXAKT德国艾卡特3D打印材料分散用三辊研磨机80E PLUS
+1/81
招聘:中国科学院山西煤炭化学研究所
+1/79
双一流南京医科大学招计算机、AI、统计、生物信息等方向26年9月入学博士
+1/77
锌离子混合电容器
+1/72
时间的眼神
+1/56
昆士兰科技大学(QUT)博士招生信息 导师:李志勇教授
+1/35
墨子实验室理论模拟研究组诚聘海内外优秀人才
+1/24
求助寒假实习
+1/20
山东理工大学资源与环境工程学院陶东平教授课题组招收2026级博士研究生
+1/13
深圳市中西医结合医院博士后招聘【药理学/中药学/天然药物/生物技术】
+1/9
天津理工大学材料学院陈民芳课题组诚招2026年秋季入学博士生
+1/6
[请教]审稿意见回复
+1/6
武汉双一流高校干细胞与肿瘤生物学团队招聘2026级申请考核制博士生
+1/6
【博士后/科研助理招聘-北京理工大学-集成电路与电子学院-国家杰青团队】
+1/5
香港中文大学(深圳)管君课题组 微纳光学方向 招收硕士、博士、博士后
+1/3
液晶拓扑光子学博士招生(电子科技大学)
+1/1
湖南大学JQ团队段辉高教授课题组招光学、算法博士啦!2026级,2个名额,等你加入!
+1/1
寻找part-time或full time的药品注册工作
+1/1
2楼2011-03-18 12:51:27
★ ★ ★
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢! 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与! 2011-03-18 21:04:15
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢! 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与! 2011-03-18 21:04:15
|
Fexofenadine hydrochloride Cas number: 153439-40-8, 138452-21-8 - General description: Fexofenadine (trade names Allegra, Telfast, Fastofen, Tilfur, Vifas, Telfexo, Allerfexo) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine (trade names include Triludan and Seldane), an antihistamine which caused QT interval prolongation, potentially leading to cardiac arrhythmia. It has been described as both second-generation[3] and third-generation antihistamine. The older antihistaminic agent terfenadine was found to metabolize into the related carboxylic acid, fexofenadine. Fexofenadine was found to retain all of the biological activity of its parent while giving fewer adverse reactions in patients, so terfenadine was replaced in the market by its metabolite.[8] Fexofenadine was originally synthesized in 1993 by Massachusetts-based biotechnology company Sepracor, which then sold the development rights to Hoechst Marion Roussel (now part of Sanofi-Aventis), and was later approved by the Food and Drug Administration (FDA) in 1996. AMRI holds the patents to the intermediates and production of fexofenadine HCl along with Roussel. Since that time, it has achieved blockbuster drug status with global sales of $1.87B USD in 2004 (with $1.49B USD coming from the United States). AMRI received royalty payments from Aventis that enabled the growth of AMRI. On January 25, 2011, the FDA approved over-the-counter sales of fexofenadine in the United States, with Sanofi-Aventis' version expected to become available on March 4, 2011. I. Originator:Aventis Pharma, Sepracor; Marketer: ViroPharma; Reference patent: JP 1996502022; WO 9321156; II. Main Competitors in U.S: N021963 Yes FEXOFENADINE HYDROCHLORIDE SUSPENSION; ORAL 30MG/5ML ALLEGRA SANOFI AVENTIS US -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076236 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A079043 No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 180MG;240MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076298 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE IMPAX PHARMS III. China Domestic Market I suggest you to look through the SFDA website to get related informations. It is not difficult. IV. The market information is not easy to acquire. I suggest you to purchase IMS data or BMI data. |
3楼2011-03-18 13:36:14
4楼2011-03-18 20:10:17
5楼2011-03-18 21:35:10
6楼2011-03-29 08:47:19












回复此楼
我主要是为了赚BB